Provided by Tiger Trade Technology Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

15.27
-0.1400-0.91%
Post-market: 15.790.5200+3.41%19:30 EDT
Volume:2.93M
Turnover:45.14M
Market Cap:2.30B
PE:-3.41
High:15.79
Open:15.46
Low:15.18
Close:15.41
52wk High:18.57
52wk Low:7.48
Shares:150.42M
Float Shares:117.99M
Volume Ratio:0.51
T/O Rate:2.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4800
EPS(LYR):-6.8648
ROE:-799.46%
ROA:-71.98%
PB:187.93
PE(LYR):-2.22

Loading ...

Biohaven Promotes David Pirman to EVP, Head of Discovery

Reuters
·
Jul 10

Press Release: Biohaven Announces Scientific Leadership Transitions

Dow Jones
·
Jul 10

Analysts’ Top Healthcare Picks: Heart Test Laboratories, Inc. (HSCS), Biohaven Ltd. (BHVN)

TIPRANKS
·
Jul 01

Biohaven announces completion of enrollment in RISE3 trial

TIPRANKS
·
Jun 30

Biohaven - Completes Enrollment in Rise3 Pivotal Phase 2/3 Focal Epilepsy Study with Opakalim

THOMSON REUTERS
·
Jun 30

Biohaven - Top-line Results from Rise3 Study Expected in Second Half of 2026

THOMSON REUTERS
·
Jun 30

Biohaven Completes Enrollment in RISE3 Pivotal Opakalim Focal Epilepsy Trial, Data Due 2H 2026

Reuters
·
Jun 30

Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at Bofa

Dow Jones
·
Jun 30

Biohaven falls -9.8%

TIPRANKS
·
Jun 29

Biohaven Cut to Underperform from Neutral by B of a Securities

Dow Jones
·
Jun 29

BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target

MT Newswires Live
·
Jun 29

Biohaven Starts Pivotal Phase 3 Trial of Bhv-1300 in Graves' Disease

Reuters
·
Jun 29

Biohaven Advances a New Class of Precision Immunology Therapies: First Mode Extracellular Protein Degrader, Bhv-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

THOMSON REUTERS
·
Jun 29

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 29

Biohaven rises 7.4%

TIPRANKS
·
Jun 26

U.S. Research Roundup-american Tower, H.B. Fuller Company, TD Synnex

Reuters
·
Jun 26

Biohaven's Troriluzole Could Drive Potential Upside if the Company Overcomes Regulatory Hurdles, RBC Says

MT Newswires Live
·
Jun 25

RBC Capital Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)

TIPRANKS
·
Jun 25

Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), Biohaven Ltd. (BHVN) and BioLife Solutions (BLFS)

TIPRANKS
·
Jun 25

Biohaven (BHVN) Is Up 22.2% After Advancing Multiple Immunology And Oncology Candidates To Pivotal Trials

Simply Wall St.
·
Jun 24